Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

@article{You2009PotentialCA,
  title={Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.},
  author={Joyce H S You and Kia K. N. Tsui and Raymond S M Wong and Gregory Cheng},
  journal={Clinical pharmacology and therapeutics},
  year={2009},
  volume={86 5},
  pages={540-7}
}
The US Food and Drug Administration has updated the label information for warfarin to encourage the use of genetic information before initiating treatment with the drug. We used decision-tree modeling to simulate the outcomes of CYP2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotype-guided dosing in patients in whom warfarin therapy is to be initiated. The inputs for the model were derived from the literature. The incremental costs per unit outcome improved (ICERs) were US$347,059… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 54 references

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

J. Ansell, J. Hirsh, +5 authors management of the vitamin K antagonists
Chest 133, 160S–198S • 2008

Health-care systems and pharmacoeconomic research in Asia-Pacific region.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2008

Physicians Evidence - Based Clinical Practice Guidelines ( 8 th Edition )

J. H. You, F. W. Chan, R. S. Wong, G. Cheng
2008

Similar Papers

Loading similar papers…